Matching articles for "Trumenba"

Adult Immunization

   
The Medical Letter on Drugs and Therapeutics • October 17, 2022;  (Issue 1661)
The Advisory Committee on Immunization Practices (ACIP) recommends use of certain vaccines in adults residing in the US. Routine childhood immunization has reduced the overall incidence of some of these...
The Advisory Committee on Immunization Practices (ACIP) recommends use of certain vaccines in adults residing in the US. Routine childhood immunization has reduced the overall incidence of some of these vaccine-preventable diseases, but many adults remain susceptible. Recommendations for vaccination against COVID-19, seasonal influenza, and monkeypox and vaccination of travelers have been reviewed separately.
Med Lett Drugs Ther. 2022 Oct 17;64(1661):161-8 | Show Full IntroductionHide Full Introduction

Expanded Table: Some Vaccines for Adults (online only)

   
The Medical Letter on Drugs and Therapeutics • October 17, 2022;  (Issue 1661)
...
Med Lett Drugs Ther. 2022 Oct 17;64(1661):e170-3 | Show Full IntroductionHide Full Introduction

MenQuadfi - A New Meningococcal (A, C, W, and Y) Vaccine

   
The Medical Letter on Drugs and Therapeutics • May 17, 2021;  (Issue 1624)
The FDA has licensed MenQuadfi (Sanofi Pasteur), a quadrivalent polysaccharide conjugate vaccine that uses tetanus toxoid as a protein carrier, for prevention of invasive meningococcal disease caused by...
The FDA has licensed MenQuadfi (Sanofi Pasteur), a quadrivalent polysaccharide conjugate vaccine that uses tetanus toxoid as a protein carrier, for prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y (MenACWY) in persons ≥2 years old.
Med Lett Drugs Ther. 2021 May 17;63(1624):78-80 | Show Full IntroductionHide Full Introduction

In Brief: New Meningococcal Serogroup B Vaccination Recommendations

   
The Medical Letter on Drugs and Therapeutics • November 30, 2020;  (Issue 1612)
The Advisory Committee on Immunization Practices (ACIP) has issued new recommendations for meningococcal vaccination. Booster vaccination against Neisseria meningitidis serogroup B (MenB) is now recommended...
The Advisory Committee on Immunization Practices (ACIP) has issued new recommendations for meningococcal vaccination. Booster vaccination against Neisseria meningitidis serogroup B (MenB) is now recommended in persons at increased risk for meningococcal disease (see Table 1). MenB booster doses were not recommended previously for any population.
Med Lett Drugs Ther. 2020 Nov 30;62(1612):191-2 | Show Full IntroductionHide Full Introduction

Vaccines for Travelers

   
The Medical Letter on Drugs and Therapeutics • November 19, 2018;  (Issue 1560)
Persons planning to travel outside the US should be up to date on routine vaccines and, depending on their destination, duration of travel, and planned activities, may also receive certain travel-specific...
Persons planning to travel outside the US should be up to date on routine vaccines and, depending on their destination, duration of travel, and planned activities, may also receive certain travel-specific vaccines. Tickborne encephalitis and dengue vaccines, which are not available in the US, are reviewed in a separate article available online. Detailed advice for travel to specific destinations is available from the Centers for Disease Control and Prevention (CDC) at www.cdc.gov/travel/destinations/list. Recommendations for administration of vaccines as part of routine adult immunization are discussed in a separate issue.
Med Lett Drugs Ther. 2018 Nov 19;60(1560):185-92 | Show Full IntroductionHide Full Introduction

Adult Immunization

   
The Medical Letter on Drugs and Therapeutics • May 7, 2018;  (Issue 1546)
The US Advisory Committee on Immunization Practices (ACIP) recommends routine use of the following vaccines in adults residing in the US: influenza, tetanus/diphtheria alone (Td) and in combination with...
The US Advisory Committee on Immunization Practices (ACIP) recommends routine use of the following vaccines in adults residing in the US: influenza, tetanus/diphtheria alone (Td) and in combination with acellular pertussis (Tdap), measles/mumps/rubella (MMR), varicella (VAR), herpes zoster (RZV; ZVL), human papillomavirus (HPV), and pneumococcal conjugate (PCV13) and polysaccharide (PPSV23) vaccines. For adults with certain medical conditions or occupational, behavioral, or other risk factors, hepatitis A (HepA), hepatitis B (HepB), meningococcal (MenACWY; MenB), and Haemophilus influenzae type b (Hib) vaccines are also recommended. Recommendations for vaccination against seasonal influenza and vaccination of travelers are reviewed separately.
Med Lett Drugs Ther. 2018 May 7;60(1546):73-82 | Show Full IntroductionHide Full Introduction

Expanded Table: Some Vaccines Recommended for Use in Adults (online only)

   
The Medical Letter on Drugs and Therapeutics • May 7, 2018;  (Issue 1546)
...
View the Expanded Table: Some Vaccines Recommended for Use in Adults
Med Lett Drugs Ther. 2018 May 7;60(1546):e82-5 | Show Full IntroductionHide Full Introduction

In Brief: New Adult Immunization Recommendations

   
The Medical Letter on Drugs and Therapeutics • April 24, 2017;  (Issue 1519)
The 2017 adult immunization schedule approved by the CDC's Advisory Committee on Immunization Practices (ACIP) includes some new or revised recommendations.1 The complete schedule is available on the CDC's...
The 2017 adult immunization schedule approved by the CDC's Advisory Committee on Immunization Practices (ACIP) includes some new or revised recommendations.1 The complete schedule is available on the CDC's website (www.cdc.gov/vaccines/schedule). New recommendations for use of influenza vaccine during the 2016-2017 season were included in a previous issue of The Medical Letter.2 Updated recommendations for other vaccines are summarized below. Recommendations for routine use of vaccines in adults were reviewed in an earlier issue.3

  1. DK Kim et al. Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older – United States, 2017. MMWR Morb Mortal Wkly Rep 2017; 66:136.
  2. Influenza vaccine for 2016-2017. Med Lett Drugs Ther 2016; 58:127.
  3. Adult immunization. Treat Guidel Med Lett 2014; 12:39.
  4. Gardasil 9 – a broader HPV vaccine. Med Lett Drugs Ther 2015; 57:47.
  5. Trumenba: a serogroup B meningococcal vaccine. Med Lett Drugs Ther 2015; 57:5.
  6. Bexsero – a second serogroup B meningococcal vaccine. Med Lett Drugs Ther 2015; 57:158.


Download complete U.S. English article

Med Lett Drugs Ther. 2017 Apr 24;59(1519):70 | Show Full IntroductionHide Full Introduction

Bexsero - A Second Serogroup B Meningococcal Vaccine

   
The Medical Letter on Drugs and Therapeutics • November 23, 2015;  (Issue 1482)
The FDA has approved Bexsero (Novartis/GSK), a vaccine that protects against invasive meningococcal disease caused by Neisseria meningitidis serogroup B. It is the second serogroup B meningococcal...
The FDA has approved Bexsero (Novartis/GSK), a vaccine that protects against invasive meningococcal disease caused by Neisseria meningitidis serogroup B. It is the second serogroup B meningococcal vaccine to be approved in the US; Trumenba was the first. Both vaccines are approved for use in persons 10-25 years old. Bexsero is approved in Europe, Canada, and Australia for use in children as young as 2 months old.
Med Lett Drugs Ther. 2015 Nov 23;57(1482):158-9 | Show Full IntroductionHide Full Introduction

Trumenba: A Serogroup B Meningococcal Vaccine

   
The Medical Letter on Drugs and Therapeutics • January 5, 2015;  (Issue 1459)
The FDA has approved Trumenba (Pfizer), a vaccine that protects against invasive meningococcal disease caused by Neisseria meningitidis serogroup B, for use in adolescents and young adults 10-25 years...
The FDA has approved Trumenba (Pfizer), a vaccine that protects against invasive meningococcal disease caused by Neisseria meningitidis serogroup B, for use in adolescents and young adults 10-25 years old.
Med Lett Drugs Ther. 2015 Jan 5;57(1459):5-6 | Show Full IntroductionHide Full Introduction